Damora Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2026; filed November 4, 2026. Amounts below are U.S. dollars. Damora is a clinical-stage biotechnology company developing antibody therapies for mutant-calreticulin (mutCALR)-driven blood disorders. It has no approved products and has not generated product revenue.
Key financial results
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $25.5 million | $1.4 million | $74.8 million | $3.6 million |
| General and administrative expense | $11.4 million | $1.7 million | $27.9 million | $5.6 million |
| Net loss | $32.0 million | $3.1 million | $90.9 million | $9.1 million |
| Net loss per ordinary share, basic and diluted | $0.40 | $2.36 | $1.19 | $6.88 |
| Net cash used in operating activities | Not provided quarterly | $59.7 million | $7.3 million |
Operating margins are not meaningful because the company reported no revenue and incurred operating losses. Other income was $4.9 million in Q3 and $12.0 million for the nine-month period, primarily interest income, plus a $0.75 million gain on sale of legacy intellectual property. Interest income was $4.2 million and $11.3 million, respectively.
Financial position and liquidity
- At September 30, 2026, cash and cash equivalents were $349.7 million and marketable securities were $178.8 million, totaling $528.5 million. Current assets were $531.3 million; current liabilities were $35.9 million.
- Total liabilities were $36.9 million and shareholders’ equity was $495.8 million. The filing does not report debt as a material balance; lease liabilities totaled approximately $1.1 million.
- Cash increased by $92.1 million over the first nine months. Financing provided $330.5 million, principally from the February public offering and ATM sales; investing used $178.8 million, principally to purchase marketable securities.
- The company raised approximately $295.5 million net in its February 2026 offering and $34.3 million net through its ATM program during the first nine months. The ATM program had $114.7 million of capacity remaining at September 30.
- Management estimates existing cash, cash equivalents and marketable securities will fund operations into the second half of 2029, subject to assumptions that could prove incorrect. The notes separately state that resources cover at least one year from issuance of the financial statements.
Material changes and notable items
- Losses and expenses increased substantially year over year as Damora expanded research, clinical, manufacturing and corporate activities. Nine-month R&D expense rose by $71.2 million; G&A rose by $22.3 million.
- Damora initiated the Phase 1/1b CLARITY-101 trial of DMR-001 in essential thrombocythemia and myelofibrosis after Australian authorization, and subsequently received FDA clearance to begin the trial in the United States.
- In March 2026, the company prioritized its mutCALR antibody portfolio and deprioritized GB3226. In Q3, it sold GB3226 and other legacy assets for $0.75 million upfront, with possible additional milestone and royalty consideration.
- On July 16, 2026, Damora redomesticated from Delaware to the Cayman Islands. It states that it remains treated as a U.S. corporation for U.S. tax purposes.
- The company issued 16.6 million ordinary shares in the February offering and sold 1.4 million shares through the ATM during the nine-month period. Ordinary shares outstanding were 61.9 million at September 30 and November 2. Series B and Series C preferred shares also remained outstanding and are convertible into ordinary shares, subject to terms and ownership limits.
- Share-based compensation was $28.7 million for the first nine months, including $11.9 million related to the Paramora warrant obligation. Total unrecognized compensation expense was $107.6 million at September 30.
Outlook, commentary and risks
- Management plans to submit the first regulatory application for DMR-002 in Q4 2026 and for DMR-003 in 2027. It expects two DMR-001 proof-of-concept readouts beginning mid-2027, plans expansion cohorts in 2027, and says Phase 3 development could begin as early as mid-2028, subject to trial results.
- On November 3, 2026, after the quarter end, Damora entered into an exclusive worldwide license agreement with related party Paragon for DMR-001 and DMR-002. Potential milestones are up to $22 million per licensed product, inclusive of previously paid milestones; a $2.5 million payment is due upon first human dosing in a Phase 1 trial. Tiered royalties are low-to-mid single digits on net sales.
- Damora expects losses and R&D spending to continue and increase. Further capital will be required for development and potential commercialization; additional financing may dilute shareholders or may not be available on acceptable terms.
- Key risks include early-stage clinical and regulatory uncertainty, dependence on DMR-001 and third parties including Paragon, manufacturing and supply concentration, competition, patient enrollment, limited and developing intellectual property protection, and macroeconomic, geopolitical and tariff-related disruption.
- The filing reports no material legal proceedings. Disclosure controls and procedures were assessed as effective at the reasonable assurance level; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Progress, enrollment, safety and timing of CLARITY-101, and whether the planned 2027 readouts and later development milestones remain achievable.
- Cash burn and runway assumptions underlying management’s second-half-2029 estimate, especially as clinical and manufacturing spending rises.
- Terms and financial impact of the November 3 Paragon license, remaining DMR-003 option, related-party governance, milestone obligations and royalties.
- Potential dilution from preferred-share conversions, equity compensation, warrants and further ATM sales.
- Manufacturing and supply risks, including reliance on third-party providers, and the potential impact of trade restrictions and tariffs.